NCT06781125 2025-01-17
One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors
Immorna Biotherapeutics, Inc.
Phase 1 Not yet recruiting
Immorna Biotherapeutics, Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Changchun GeneScience Pharmaceutical Co., Ltd.
Sanofi
AstraZeneca